Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$3.93 +0.3%	$4.16	$1.00 ▼ $5.87	$34.88M	0.8	145,111 shs	66,743 shs
IPA ImmunoPrecise Antibodies	$1.11	$0.62	$0.27 ▼ $1.16	$50.80M	0.12	2.52 million shs	1.09 million shs
KPTI Karyopharm Therapeutics	$4.39 -2.2%	$5.11	$3.51 ▼ $16.95	$37.93M	0.23	77,090 shs	32,788 shs
TLPH Talphera	$0.47 +6.4%	$0.50	$0.43 ▼ $1.19	$9.60M	-0.11	70,820 shs	164,215 shs

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	0.00%	-7.09%	-14.47%	+14.24%	+120.60%
IPA ImmunoPrecise Antibodies	0.00%	+10.45%	+93.31%	+183.16%	+10.45%
KPTI Karyopharm Therapeutics	0.00%	+0.23%	-3.09%	+5.53%	-70.59%
TLPH Talphera	0.00%	+2.74%	-4.29%	-20.14%	-46.82%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATHE Alterity Therapeutics	2.6399 of 5 stars	3.3	5.0	0.0	2.2	1.7	0.0
IPA ImmunoPrecise Antibodies	2.3247 of 5 stars	3.5	3.0	0.0	2.7	0.0	0.6
KPTI Karyopharm Therapeutics	4.1565 of 5 stars	3.5	1.0	4.6	2.7	2.5	0.6
TLPH Talphera	2.5299 of 5 stars	3.8	3.0	0.0	2.7	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.50	Moderate Buy	$12.00	205.34% Upside
IPA ImmunoPrecise Antibodies	3.00	Buy	$4.00	260.36% Upside
KPTI Karyopharm Therapeutics	3.00	Buy	$43.20	884.05% Upside
TLPH Talphera	3.50	Strong Buy	$5.00	968.38% Upside

Current Analyst Ratings Breakdown

Latest TLPH, KPTI, ATHE, and IPA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00
5/13/2025	KPTI Karyopharm Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$5.00 ➝ $10.00
5/13/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$54.00 ➝ $42.00
4/11/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/1/2025	IPA ImmunoPrecise Antibodies	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Speculative Buy ➝ Speculative Buy	$3.00 ➝ $3.00
4/1/2025	TLPH Talphera	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $6.00
3/31/2025	IPA ImmunoPrecise Antibodies	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$7.00 ➝ $5.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.04 per share	N/A
IPA ImmunoPrecise Antibodies	$18.16M	2.80	N/A	N/A	$0.93 per share	1.19
KPTI Karyopharm Therapeutics	$145.24M	0.26	N/A	N/A	($22.10) per share	-0.20
TLPH Talphera	$650K	14.76	N/A	N/A	$0.47 per share	1.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/4/2025 (Estimated)
IPA ImmunoPrecise Antibodies	-$20.13M	-$1.16	N/A	N/A	N/A	-190.76%	-88.87%	-49.26%	7/3/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$13.26	N/A	N/A	N/A	-43.99%	N/A	-35.95%	8/5/2025 (Estimated)
TLPH Talphera	-$13M	-$0.45	N/A	N/A	N/A	N/A	-130.28%	-59.25%	8/13/2025 (Estimated)

Latest TLPH, KPTI, ATHE, and IPA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
3/31/2025	Q4 2024	TLPH Talphera	-$0.21	-$0.07	+$0.14	-$0.07	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
IPA ImmunoPrecise Antibodies	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
TLPH Talphera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	3.84	N/A
IPA ImmunoPrecise Antibodies	0.45	2.32	2.11
KPTI Karyopharm Therapeutics	N/A	1.33	1.28
TLPH Talphera	N/A	3.11	3.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
IPA ImmunoPrecise Antibodies	6.70%
KPTI Karyopharm Therapeutics	66.44%
TLPH Talphera	37.67%

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
IPA ImmunoPrecise Antibodies	6.83%
KPTI Karyopharm Therapeutics	2.98%
TLPH Talphera	3.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.43 million	Not Optionable
IPA ImmunoPrecise Antibodies	80	45.76 million	42.64 million	Not Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	8.38 million	Optionable
TLPH Talphera	19	20.50 million	19.85 million	Optionable

TLPH, KPTI, ATHE, and IPA Headlines

Recent News About These Companies

talphera receives extension to meet nasdaq listing requirements

June 7, 2025 | investing.com

Talphera Granted Extension for Nasdaq Compliance

June 5, 2025 | tipranks.com

Talphera, Inc.: Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 17, 2025 | finanznachrichten.de

Earnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025

May 16, 2025 | uk.investing.com

Talphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call Transcript

May 16, 2025 | msn.com

Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing

May 15, 2025 | msn.com

Talphera, Inc. (TLPH) Q1 2025 Earnings Call Transcript

May 14, 2025 | seekingalpha.com

Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025 | prnewswire.com

Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025

May 7, 2025 | prnewswire.com

All You Need to Know About Talphera (TLPH) Rating Upgrade to Strong Buy

May 7, 2025 | msn.com

Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock?

April 5, 2025 | msn.com

Talphera reports Q4 EPS (7c) vs. (25c) last year

April 1, 2025 | markets.businessinsider.com

Talphera, Inc. (NASDAQ:TLPH) Q4 2024 Earnings Call Transcript

April 1, 2025 | msn.com

Talphera announces agreement with FDA to reduce NEPHRO CRRT study size

April 1, 2025 | markets.businessinsider.com

Talphera Reports 2024 Financial Results and Study Update

March 31, 2025 | tipranks.com

Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad

March 31, 2025 | msn.com

Talphera, Inc. (TLPH) Q4 2024 Earnings Call Transcript

March 31, 2025 | seekingalpha.com

Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

March 31, 2025 | prnewswire.com

Talphera Announces Agreement with the FDA to Reduce the NEPHRO CRRT Study Size to 70 Patients From 166 and a Private Placement Financing Priced At-the Market of up to $14.8 Million

March 31, 2025 | prnewswire.com

7TLPH : Earnings Outlook For Talphera

March 28, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TLPH, KPTI, ATHE, and IPA Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

$3.93 +0.01 (+0.26%)

Closing price 06/27/2025 03:57 PM Eastern

Extended Trading

$4.00 +0.06 (+1.65%)

As of 06/27/2025 04:04 PM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

ImmunoPrecise Antibodies NASDAQ:IPA

$1.11 0.00 (0.00%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.10 -0.02 (-1.35%)

As of 06/27/2025 07:56 PM Eastern

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

Karyopharm Therapeutics NASDAQ:KPTI

$4.39 -0.10 (-2.23%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$4.39 +0.00 (+0.11%)

As of 06/27/2025 04:04 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Talphera NASDAQ:TLPH

$0.47 +0.03 (+6.36%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.47 +0.00 (+0.64%)

As of 06/27/2025 04:26 PM Eastern

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time